Switching from ligand to receptor anti‐calcitonin gene‐related peptide (<scp>CGRP</scp>) antibodies or vice versa in non‐responders: A controlled cohort study
Transitioning to a different anti-calcitonin gene-related peptide monoclonal class yields reduction in monthly migraine days compared to returning to standard care for patients with inadequate initial treatment response.
Authors
- Erik W. van Zwet (ORCID: https://orcid.org/0000-0001-5537-3179)
- Gisela M. Terwindt (ORCID: https://orcid.org/0000-0003-3140-6882)
- Britt W. H. van der Arend (ORCID: https://orcid.org/0000-0001-8999-0087)
- Nancy van Veelen (ORCID: https://orcid.org/0000-0002-3558-8065)
- E. Hiele
Institutions
- Leiden University Medical Center (NL)
- Erasmus MC (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- European Journal of Neurology
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1111/ene.16542
- Citations
- 5
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.93